| Name | Title | Contact Details |
|---|
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Planned Parenthood Federation of America is a nonprofit organization that provides sexual health care in the United States and globally. They are a trusted health care provider, an informed educator, a passionate advocate, and a global partner helping ...
Speciality Medical Billing is a Templeton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
NationsHealth, Inc. provides medical products nationwide to Medicare and managed care beneficiaries.
Pacific Health Care Supplies is a Richmond, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.